3vfv
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
==crystal structure of HLA B*3508 LPEP-P9Ala, peptide mutant P9-ala== | ==crystal structure of HLA B*3508 LPEP-P9Ala, peptide mutant P9-ala== | ||
- | <StructureSection load='3vfv' size='340' side='right' caption='[[3vfv]], [[Resolution|resolution]] 1.55Å' scene=''> | + | <StructureSection load='3vfv' size='340' side='right'caption='[[3vfv]], [[Resolution|resolution]] 1.55Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[3vfv]] is a 3 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[3vfv]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3VFV OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3VFV FirstGlance]. <br> |
- | </td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1zhk|1zhk]], [[1zhl|1zhl]], [[2ak4|2ak4]], [[3vfm|3vfm]], [[3vfn|3vfn]], [[3vfo|3vfo]], [[3vfp|3vfp]], [[3vfr|3vfr]], [[3vfs|3vfs]], [[3vft|3vft]], [[3vfu|3vfu]], [[3vfw|3vfw]]</td></tr> | + | </td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[1zhk|1zhk]], [[1zhl|1zhl]], [[2ak4|2ak4]], [[3vfm|3vfm]], [[3vfn|3vfn]], [[3vfo|3vfo]], [[3vfp|3vfp]], [[3vfr|3vfr]], [[3vfs|3vfs]], [[3vft|3vft]], [[3vfu|3vfu]], [[3vfw|3vfw]]</div></td></tr> |
- | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">HLA-B ([ | + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">HLA-B ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), B2M, CDABP0092, HDCMA22P ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3vfv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3vfv OCA], [https://pdbe.org/3vfv PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3vfv RCSB], [https://www.ebi.ac.uk/pdbsum/3vfv PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3vfv ProSAT]</span></td></tr> |
</table> | </table> | ||
== Disease == | == Disease == | ||
- | [[ | + | [[https://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP) [MIM:[https://omim.org/entry/241600 241600]]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation.<ref>PMID:16549777</ref> Note=Beta-2-microglobulin may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta(2)-microglobulin serum levels lead to amyloidosis in patients on long-term hemodialysis.<ref>PMID:3532124</ref> <ref>PMID:1336137</ref> <ref>PMID:7554280</ref> <ref>PMID:4586824</ref> <ref>PMID:8084451</ref> <ref>PMID:12119416</ref> <ref>PMID:12796775</ref> <ref>PMID:16901902</ref> <ref>PMID:16491088</ref> <ref>PMID:17646174</ref> <ref>PMID:18835253</ref> <ref>PMID:18395224</ref> <ref>PMID:19284997</ref> |
== Function == | == Function == | ||
- | [[ | + | [[https://www.uniprot.org/uniprot/C5MK56_HUMAN C5MK56_HUMAN]] Involved in the presentation of foreign antigens to the immune system (By similarity).[SAAS:SAAS003006_004_004364] [[https://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. |
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 23: | Line 23: | ||
==See Also== | ==See Also== | ||
- | *[[Beta-2 microglobulin|Beta-2 microglobulin]] | + | *[[Beta-2 microglobulin 3D structures|Beta-2 microglobulin 3D structures]] |
== References == | == References == | ||
<references/> | <references/> | ||
Line 29: | Line 29: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | [[Category: Human]] | ||
+ | [[Category: Large Structures]] | ||
[[Category: Gras, S]] | [[Category: Gras, S]] | ||
[[Category: Liu, Y C]] | [[Category: Liu, Y C]] |
Revision as of 18:43, 27 July 2022
crystal structure of HLA B*3508 LPEP-P9Ala, peptide mutant P9-ala
|